US5908621A
(en)
|
1995-11-02 |
1999-06-01 |
Schering Corporation |
Polyethylene glycol modified interferon therapy
|
PT858343E
(pt)
|
1995-11-02 |
2004-07-30 |
Schering Corp |
Terapia por infusao continua de uma dose baixa de citoquina
|
US20030190307A1
(en)
*
|
1996-12-24 |
2003-10-09 |
Biogen, Inc. |
Stable liquid interferon formulations
|
US7270809B2
(en)
*
|
1997-07-14 |
2007-09-18 |
Bolder Biotechnology, Inc. |
Cysteine variants of alpha interferon-2
|
WO1999003887A1
(en)
*
|
1997-07-14 |
1999-01-28 |
Bolder Biotechnology, Inc. |
Derivatives of growth hormone and related proteins
|
US20080076706A1
(en)
|
1997-07-14 |
2008-03-27 |
Bolder Biotechnology, Inc. |
Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
|
US6753165B1
(en)
*
|
1999-01-14 |
2004-06-22 |
Bolder Biotechnology, Inc. |
Methods for making proteins containing free cysteine residues
|
KR100364938B1
(ko)
*
|
1997-09-18 |
2002-12-18 |
에프. 호프만-라 로슈 아게 |
만성 씨형 간염의 치료를 위한 인테페론-알파와 아만타딘을 함유한 약제
|
US6172046B1
(en)
*
|
1997-09-21 |
2001-01-09 |
Schering Corporation |
Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
|
US6180096B1
(en)
|
1998-03-26 |
2001-01-30 |
Schering Corporation |
Formulations for protection of peg-interferon alpha conjugates
|
ID28470A
(id)
*
|
1998-03-26 |
2001-05-24 |
Schering Corp |
Formulasi-formulasi untuk perlindungan terhadap konjugasi polietilen glikol-interferon alfa
|
CN1230198C
(zh)
*
|
1998-05-15 |
2005-12-07 |
先灵公司 |
给首次接受抗病毒疗法的G慢性丙型肝炎感染患者施用包括利巴韦林和α干扰素的联合疗法
|
ITMI981148A1
(it)
*
|
1998-05-22 |
1999-11-22 |
Therapicon Srl |
Utilizzo di lisozima c modificato per preparare composizioni medicinali per il trattamento di alcune gravi malattie
|
HU228218B1
(en)
*
|
1998-06-08 |
2013-02-28 |
Hoffmann La Roche |
Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c
|
AU6037499A
(en)
*
|
1998-09-14 |
2000-04-03 |
Vertex Pharmaceuticals Incorporated |
Methods of treating viral disease
|
NZ510689A
(en)
|
1998-10-16 |
2003-07-25 |
Biogen Inc |
Polymer conjugates of interferon beta-1a and uses
|
EP1121382B9
(en)
|
1998-10-16 |
2007-07-04 |
Biogen Idec MA Inc. |
Interferon-beta fusion proteins and uses
|
JP2003507322A
(ja)
*
|
1998-12-18 |
2003-02-25 |
シェリング・コーポレーション |
リバビリン−PEG化インターフェロン−α誘発HCV併用治療
|
US8288126B2
(en)
|
1999-01-14 |
2012-10-16 |
Bolder Biotechnology, Inc. |
Methods for making proteins containing free cysteine residues
|
AR029337A1
(es)
*
|
1999-03-02 |
2003-06-25 |
Schering Corp |
Uso de interferon alfa pegilado para la preparacion de un medicamento para la terapia contra el hiv
|
US6923966B2
(en)
*
|
1999-04-08 |
2005-08-02 |
Schering Corporation |
Melanoma therapy
|
US6605273B2
(en)
|
1999-04-08 |
2003-08-12 |
Schering Corporation |
Renal cell carcinoma treatment
|
WO2000061173A2
(en)
*
|
1999-04-08 |
2000-10-19 |
Schering Corporation |
Use of pegylated interferon alpha in chronic myeloid leukemia (cml) therapy
|
TWI310314B
(en)
*
|
1999-04-08 |
2009-06-01 |
Schering Corp |
Pharmaceutical compositions for treating rental cell carcinoma
|
ATE496631T1
(de)
*
|
1999-04-08 |
2011-02-15 |
Schering Corp |
Melanomtherapie
|
US6362162B1
(en)
|
1999-04-08 |
2002-03-26 |
Schering Corporation |
CML Therapy
|
US6635646B1
(en)
*
|
1999-05-04 |
2003-10-21 |
Schering Corporation |
Pegylated interferon alfa-CCR5 antagonist combination HIV therapy
|
PT1175224E
(pt)
*
|
1999-05-04 |
2005-07-29 |
Schering Corp |
Terapeutica de combinacao contra hiv com interferao-alfa peguilado e um antagonista de ccr5
|
BR0013252A
(pt)
*
|
1999-08-13 |
2002-04-16 |
Hoffmann La Roche |
Micofenolato mofetila em associação com peg-ifn-alfa
|
CA2388025A1
(en)
*
|
1999-09-29 |
2001-04-05 |
The Cleveland Clinic Foundation |
Therapy with 2-5a and interferon
|
JP2001288109A
(ja)
*
|
2000-04-06 |
2001-10-16 |
Schering Plough Corp |
黒色腫治療
|
MY164523A
(en)
*
|
2000-05-23 |
2017-12-29 |
Univ Degli Studi Cagliari |
Methods and compositions for treating hepatitis c virus
|
WO2001092282A2
(en)
*
|
2000-05-26 |
2001-12-06 |
Idenix (Cayman) Limited |
Methods and compositions for treating flaviviruses and pestiviruses
|
US7208167B2
(en)
*
|
2000-08-07 |
2007-04-24 |
Sciclone Pharmaceuticals, Inc. |
Treatment of hepatitis C with thymosin and peptide combination therapy
|
DK1311286T3
(da)
*
|
2000-08-07 |
2006-10-30 |
Sciclone Pharmaceuticals Inc |
Behandling af hepatitis C med thymosin og pegyleret interferon
|
ATE516820T1
(de)
*
|
2000-09-29 |
2011-08-15 |
Schering Corp |
Pegyliertes interleukin 10
|
WO2002036072A2
(en)
*
|
2000-11-03 |
2002-05-10 |
Biomedicines, Inc. |
Method for short-term and long-term drug dosimetry
|
AU2002227252A1
(en)
*
|
2000-12-01 |
2002-06-11 |
Cornell Research Foundation |
Animal model for flaviviridae infection
|
CA2429769C
(en)
*
|
2000-12-07 |
2016-04-26 |
Board Of Regents, The University Of Texas System |
Methods of treatment involving human mda-7
|
US6720000B2
(en)
*
|
2001-03-19 |
2004-04-13 |
Three Rivers Pharmaceutical, Llc |
Process for producing wet ribavirin pellets
|
WO2003026589A2
(en)
*
|
2001-09-28 |
2003-04-03 |
Idenix (Cayman) Limited |
Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
|
BR0213103A
(pt)
*
|
2001-10-05 |
2004-09-21 |
Intermune Inc |
Método para tratamento de infecção pelo vìrus da hepatite com um perfil de liberação de interferon multifásico
|
UA78726C2
(en)
*
|
2001-11-01 |
2007-04-25 |
Sciclone Pharmaceuticals Inc |
Pharmaceutical composition of thymosin alpha 1 conjugated with polyethylene glycol, method for production, and method for treatment
|
RU2004116821A
(ru)
*
|
2001-11-02 |
2005-04-20 |
Сандоз Инк. (Us) |
Способ получения быстрорастворимой композиции с высоким содержанием рибавирина
|
IL161889A0
(en)
*
|
2001-11-09 |
2005-11-20 |
Biomedicines Inc |
Method for treating diseases with omega interferon
|
KR100480429B1
(ko)
*
|
2001-12-04 |
2005-04-06 |
선바이오(주) |
인터페론-알파와 폴리에틸렌글리콜 유도체의 배합체
|
JP2005517648A
(ja)
*
|
2001-12-07 |
2005-06-16 |
インターミューン インコーポレイテッド |
肝炎ウイルス感染症を治療するための組成物および方法
|
ES2774801T3
(es)
*
|
2002-01-18 |
2020-07-22 |
Biogen Ma Inc |
Compuestos de polímero de polialquileno y usos de los mismos
|
WO2003068162A2
(en)
*
|
2002-02-14 |
2003-08-21 |
Pharmasset Ltd. |
Modified fluorinated nucleoside analogues
|
CA2477780A1
(en)
*
|
2002-03-05 |
2003-09-18 |
Board Of Regents, The University Of Texas System |
Methods of enhancing immune induction involving mda-7
|
US20040034206A1
(en)
*
|
2002-05-31 |
2004-02-19 |
Schering Corporation |
Combination therapy for RNA virus infections involving ribavirin and IMPDH inhibitors
|
KR20050035194A
(ko)
*
|
2002-06-28 |
2005-04-15 |
이데닉스 (케이만) 리미티드 |
플라비비리다에 감염 치료용 2'-c-메틸-3'-o-l-발린에스테르 리보푸라노실 사이티딘
|
US7608600B2
(en)
*
|
2002-06-28 |
2009-10-27 |
Idenix Pharmaceuticals, Inc. |
Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
|
CN101172993A
(zh)
*
|
2002-06-28 |
2008-05-07 |
埃迪尼克斯(开曼)有限公司 |
用于治疗黄病毒感染的2′-c-甲基-3′-o-l-缬氨酸酯核糖呋喃基胞苷
|
ES2469569T3
(es)
|
2002-06-28 |
2014-06-18 |
Idenix Pharmaceuticals, Inc. |
Prof�rmacos de nucle�sidos modificados en 2' y 3' para el tratamiento de infecciones de Flaviviridae
|
ATE386054T1
(de)
|
2002-08-31 |
2008-03-15 |
Cj Corp |
Glycosylierte humane interferon alpha isoform
|
US7538094B2
(en)
*
|
2002-09-19 |
2009-05-26 |
Three Rivers Pharmacueticals, Llc |
Composition containing ribavirin and use thereof
|
WO2004041071A2
(en)
*
|
2002-11-04 |
2004-05-21 |
4Life Research, Lc |
Compositions, systems, and methods for focusing a cell-mediated immune response
|
KR20050088079A
(ko)
|
2002-11-15 |
2005-09-01 |
이데닉스 (케이만) 리미티드 |
2'-분지형 뉴클레오시드 및 플라비비리다에 돌연변이
|
MXPA05005379A
(es)
*
|
2002-11-19 |
2006-02-17 |
Achillion Pharmaceuticals Inc |
Tioureas de arilo sustituidas y compuestos relacionados; inhibidores de duplicacion viral.
|
US7897567B2
(en)
|
2002-11-25 |
2011-03-01 |
Sciclone Pharmaceuticals, Inc. |
Methods of protecting against radiation damage using alpha thymosin
|
CA2509687C
(en)
*
|
2002-12-12 |
2012-08-14 |
Idenix (Cayman) Limited |
Process for the production of 2'-branched nucleosides
|
US7731947B2
(en)
|
2003-11-17 |
2010-06-08 |
Intarcia Therapeutics, Inc. |
Composition and dosage form comprising an interferon particle formulation and suspending vehicle
|
GB0301879D0
(en)
*
|
2003-01-27 |
2003-02-26 |
Regent Res Llp |
HCV combination therapy
|
US20070077225A1
(en)
*
|
2003-02-28 |
2007-04-05 |
Blatt Lawrence M |
Continuous delivery methods for treating hepatitis virus infection
|
WO2004078194A1
(en)
*
|
2003-02-28 |
2004-09-16 |
Intermune, Inc. |
Interferon drug therapy for the treatment of viral diseases and liver fibrosis
|
CN1759122B
(zh)
*
|
2003-03-03 |
2012-06-13 |
得克萨斯州大学系统董事会 |
包含mda-7的组合物和方法
|
WO2004093901A1
(en)
*
|
2003-03-28 |
2004-11-04 |
Intermune, Inc. |
Compositions and methods for treating poxvirus infection
|
US20100311656A1
(en)
*
|
2003-04-23 |
2010-12-09 |
Sciclone Pharmaceuticals, Inc. |
Treatment or prevention of respiratory viral infections with alpha thymosin peptides
|
LT2604620T
(lt)
|
2003-05-30 |
2016-09-12 |
Gilead Pharmasset Llc |
Modifikuoti fluorintų nukleozidų analogai
|
GB0320638D0
(en)
*
|
2003-09-03 |
2003-10-01 |
Novartis Ag |
Organic compounds
|
CA2540858C
(en)
|
2003-10-14 |
2009-12-08 |
Intermune, Inc. |
Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication
|
US8034790B2
(en)
*
|
2003-12-01 |
2011-10-11 |
Introgen Therapeutics |
Use of MDA-7 to inhibit pathogenic infectious organisms
|
GB0500020D0
(en)
|
2005-01-04 |
2005-02-09 |
Novartis Ag |
Organic compounds
|
AU2008201682B2
(en)
*
|
2004-02-02 |
2011-02-24 |
Ambrx, Inc. |
Modified human interferon polypeptides and their uses
|
AU2005209926B2
(en)
|
2004-02-02 |
2007-09-06 |
Ambrx, Inc. |
Modified human four helical bundle polypeptides and their uses
|
CN100355784C
(zh)
*
|
2004-02-12 |
2007-12-19 |
江苏恒瑞医药股份有限公司 |
聚乙二醇修饰α-干扰素1b的制备方法
|
US20070281041A1
(en)
*
|
2004-03-02 |
2007-12-06 |
Introgen Therapeutics, Inc. |
Compositions and Methods Involving MDA-7 for the Treatment of Cancer
|
WO2005107742A1
(en)
|
2004-05-05 |
2005-11-17 |
Yale University |
Novel antiviral helioxanthin analogs
|
EA011954B1
(ru)
*
|
2004-05-14 |
2009-06-30 |
Сциклон Фармасьютикалс, Инк. |
Лечение или предупреждение респираторных вирусных инфекций с помощью иммуномодуляторов
|
DE602005026294D1
(de)
*
|
2004-07-14 |
2011-03-24 |
Novartis Ag |
Verwendung einer kombination von cyclosporin und pegylierten interferonen zur behandlung von hepatitis c (hcv)
|
CN101023094B
(zh)
*
|
2004-07-21 |
2011-05-18 |
法莫赛特股份有限公司 |
烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
|
US7632491B2
(en)
|
2004-08-12 |
2009-12-15 |
Schering Corporation |
Stable pegylated interferon formulation
|
CA2580457C
(en)
|
2004-09-14 |
2014-11-04 |
Pharmasset, Inc. |
Preparation of 2'fluoro-2'-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
|
WO2006056464A2
(en)
|
2004-11-26 |
2006-06-01 |
Pieris Ag |
Compound with affinity for the cytotoxic t lymphocyte-associated antigen (ctla-4)
|
BRPI0519355A2
(pt)
*
|
2004-12-23 |
2009-01-20 |
Novartis Ag |
compostos para tratamento contra flaviviridae
|
BRPI0519345A2
(pt)
*
|
2004-12-23 |
2009-01-20 |
Novartis Ag |
composiÇço para tratamento do hcv
|
US8299025B2
(en)
|
2005-02-03 |
2012-10-30 |
Intarcia Therapeutics, Inc. |
Suspension formulations of insulinotropic peptides and uses thereof
|
US11246913B2
(en)
|
2005-02-03 |
2022-02-15 |
Intarcia Therapeutics, Inc. |
Suspension formulation comprising an insulinotropic peptide
|
WO2006083761A2
(en)
|
2005-02-03 |
2006-08-10 |
Alza Corporation |
Solvent/polymer solutions as suspension vehicles
|
WO2006086798A2
(en)
*
|
2005-02-08 |
2006-08-17 |
Board Of Regents, The University Of Texas System |
Compositions and methods involving mda-7 for the treatment of cancer
|
ES2302402B1
(es)
*
|
2005-06-16 |
2009-05-08 |
Proyecto De Biomedicina Cima, S.L. |
Uso de una citoquina de la familia de interleuquina-6 en la preparacion de una composicion para administracion combinada con interferon-alfa.
|
KR20080033274A
(ko)
|
2005-06-17 |
2008-04-16 |
노파르티스 아게 |
Hcv에서 상글리페린의 용도
|
KR20080037656A
(ko)
*
|
2005-06-20 |
2008-04-30 |
펩젠 코포레이션 |
저독성의 장시간 순환하는 사람 인터페론-알파 유사체 및인터페론 타우의 키메라
|
US7695710B2
(en)
*
|
2005-06-20 |
2010-04-13 |
Pepgen Corporation |
Antitumor and antiviral combination therapies using low-toxicity, long-circulating human interferon-alpha analogs
|
EA019888B1
(ru)
|
2005-07-25 |
2014-07-30 |
Интермьюн, Инк. |
Промежуточное соединение для получения макроциклических ингибиторов репликации вируса гепатита с и способ его синтеза
|
DK1999129T3
(da)
|
2005-10-11 |
2011-02-07 |
Intermune Inc |
Forbindelser og fremgangsmåder til inhibering af replikationen af hepatitis C-virus
|
WO2007075876A2
(en)
*
|
2005-12-23 |
2007-07-05 |
Idenix Pharmaceuticals, Inc. |
Process for preparing a synthetic intermediate for preparation of branched nucleosides
|
CA2636914C
(en)
|
2006-01-12 |
2016-08-09 |
Kuniaki Yoshioka |
Oral composition containing interferon-.alpha.
|
US20070231301A1
(en)
*
|
2006-03-31 |
2007-10-04 |
Warren Stephen L |
Parenteral low dose type 1 interferons for bladder cancer
|
RU2448976C2
(ru)
|
2006-04-11 |
2012-04-27 |
Новартис Аг |
Ингибиторы hcv/вич и их применение
|
KR101106510B1
(ko)
|
2006-05-30 |
2012-01-20 |
인타르시아 세라퓨틱스 인코포레이티드 |
투피스, 내부채널 삼투압 전달 시스템 유동 조절기
|
US8114150B2
(en)
*
|
2006-06-14 |
2012-02-14 |
Advanced Cardiovascular Systems, Inc. |
RGD peptide attached to bioabsorbable stents
|
AR078117A1
(es)
|
2006-06-20 |
2011-10-19 |
Protech Pharma S A |
Una muteina recombinante del interferon alfa humano glicosilado, un gen que codifica para dicha muteina, un metodo de produccion de dicho gen, un metodo para obtener una celula eucariota productora de dicha muteina, un metodo para producir dicha muteina, un procedimiento para purificar dicha muteina
|
EP2356990A3
(en)
|
2006-08-02 |
2011-10-19 |
University of Oxford |
Liposome treatment of viral infections
|
KR101200728B1
(ko)
|
2006-08-09 |
2012-11-13 |
인타르시아 세라퓨틱스 인코포레이티드 |
삼투성 전달 시스템 및 피스톤 조립체
|
CA2666814A1
(en)
*
|
2006-08-21 |
2008-05-29 |
United Therapeutics Corporation |
Combination therapy for treatment of viral infections
|
US8679472B1
(en)
|
2006-10-05 |
2014-03-25 |
Merck, Sharp & Dohme Corp. |
Crystal of human interferon alpha 2B in complex with zinc
|
EP2073831A1
(en)
*
|
2006-10-12 |
2009-07-01 |
Novartis AG |
Use of modified cyclosporins
|
US7964580B2
(en)
|
2007-03-30 |
2011-06-21 |
Pharmasset, Inc. |
Nucleoside phosphoramidate prodrugs
|
WO2008137471A2
(en)
|
2007-05-02 |
2008-11-13 |
Ambrx, Inc. |
Modified interferon beta polypeptides and their uses
|
CN101939443B
(zh)
|
2008-02-08 |
2014-01-29 |
Ambrx公司 |
经修饰瘦素多肽和其用途
|
EP2240155B1
(en)
|
2008-02-13 |
2012-06-06 |
Intarcia Therapeutics, Inc |
Devices, formulations, and methods for delivery of multiple beneficial agents
|
KR20100127842A
(ko)
*
|
2008-03-26 |
2010-12-06 |
유니버시티 오브 옥스퍼드 |
소포체 표적화 리포좀
|
TW200946541A
(en)
*
|
2008-03-27 |
2009-11-16 |
Idenix Pharmaceuticals Inc |
Solid forms of an anti-HIV phosphoindole compound
|
DK3050576T3
(da)
|
2008-04-29 |
2021-06-07 |
Ascendis Pharma Endocrinology Div A/S |
Pegylerede rekombinante forbindelser af humant væksthormon
|
EP2113256A1
(en)
|
2008-04-29 |
2009-11-04 |
Ascendis Pharma AS |
PEGylated rhGH compounds
|
US8173621B2
(en)
|
2008-06-11 |
2012-05-08 |
Gilead Pharmasset Llc |
Nucleoside cyclicphosphates
|
EP2313430B1
(en)
|
2008-06-24 |
2018-05-02 |
Technische Universität München |
Muteins of hngal and related proteins with affinity for a given target
|
MX2011002602A
(es)
*
|
2008-09-17 |
2011-04-07 |
Boehringer Ingelheim Int |
Combinacion de inhibidor de la proteasa ns3 de hcv con interferon y ribavirina.
|
PL2379115T3
(pl)
|
2008-12-17 |
2018-03-30 |
Merck Sharp & Dohme Corp. |
Wytwarzanie i zastosowania mono- i di-peg il-10
|
JP5713919B2
(ja)
|
2008-12-23 |
2015-05-07 |
ギリアド ファーマセット エルエルシー |
ヌクレオシドホスホラミデート
|
WO2010075554A1
(en)
|
2008-12-23 |
2010-07-01 |
Pharmasset, Inc. |
Synthesis of purine nucleosides
|
PA8855701A1
(es)
|
2008-12-23 |
2010-07-27 |
|
Análogos de nucleósidos
|
JP5576928B2
(ja)
*
|
2009-03-27 |
2014-08-20 |
ジェイダブリュ ファーマシューティカル コーポレーション |
インターフェロン−アルファ及び細胞質残留性細胞膜透過ペプチドを含むIFN−α融合タンパク質
|
WO2010109330A2
(en)
*
|
2009-03-27 |
2010-09-30 |
University Of Oxford |
Cholesterol level lowering liposomes
|
US20110182850A1
(en)
|
2009-04-10 |
2011-07-28 |
Trixi Brandl |
Organic compounds and their uses
|
US8512690B2
(en)
|
2009-04-10 |
2013-08-20 |
Novartis Ag |
Derivatised proline containing peptide compounds as protease inhibitors
|
US8618076B2
(en)
|
2009-05-20 |
2013-12-31 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
TWI598358B
(zh)
|
2009-05-20 |
2017-09-11 |
基利法瑪席特有限責任公司 |
核苷磷醯胺
|
EP2459211A1
(en)
|
2009-07-31 |
2012-06-06 |
Medtronic, Inc. |
Continuous subcutaneous administration of interferon- to hepatitis c infected patients
|
AU2010280688A1
(en)
|
2009-08-05 |
2012-02-23 |
Allergan, Inc. |
Controlled release formulations of lipocalin muteins
|
HUE035862T2
(en)
|
2009-09-28 |
2018-05-28 |
Intarcia Therapeutics Inc |
Rapid development and / or completion of substantially steady-state drug delivery
|
NZ598465A
(en)
|
2009-10-30 |
2013-10-25 |
Boehringer Ingelheim Int |
Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin
|
DK2510357T3
(da)
|
2009-12-07 |
2016-07-18 |
Pieris Ag |
Muteiner af human lipocalin 2 (lcn2, hngal) med affinitet til et specifikt mål
|
PL3290428T3
(pl)
|
2010-03-31 |
2022-02-07 |
Gilead Pharmasset Llc |
Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
|
EP2752422B1
(en)
|
2010-03-31 |
2017-08-16 |
Gilead Pharmasset LLC |
Stereoselective synthesis of phosphorus containing actives
|
LT2580236T
(lt)
|
2010-06-08 |
2019-06-25 |
Pieris Pharmaceuticals Gmbh |
Ašarų lipokalino muteinai, surišantys il-4 r alfa
|
WO2011159930A2
(en)
|
2010-06-16 |
2011-12-22 |
Medtronic, Inc. |
Damping systems for stabilizing medications in drug delivery devices
|
CA2803093A1
(en)
|
2010-06-24 |
2011-12-29 |
Panmed Ltd. |
Treatment of hepatitis c virus related diseases using hydroxychloroquine or a combination of hydroxychloroquine and an anti-viral agent
|
US9051382B2
(en)
|
2010-08-16 |
2015-06-09 |
Pieris Ag |
Human neutrophil gelatinase-associated lipocalin (hNGAL) muteins that bind hepcidin and nucleic acid encoding such
|
JP2013542206A
(ja)
|
2010-10-05 |
2013-11-21 |
ノバルティス アーゲー |
C型肝炎ウイルス感染症の新規治療
|
WO2012048235A1
(en)
|
2010-10-08 |
2012-04-12 |
Novartis Ag |
Vitamin e formulations of sulfamide ns3 inhibitors
|
DK2640740T3
(da)
|
2010-11-15 |
2017-06-26 |
Pieris Pharmaceuticals Gmbh |
Muteiner af human lipocalin 2 med affinitet til glypican-3 (gpc3)
|
MX2013006052A
(es)
|
2010-11-30 |
2013-06-18 |
Novartis Ag |
Nuevos tratamientos de la infeccion por el virus de hepatitis c.
|
TW201242974A
(en)
|
2010-11-30 |
2012-11-01 |
Gilead Pharmasset Llc |
Compounds
|
US9221885B2
(en)
|
2010-12-02 |
2015-12-29 |
Pieris Ag |
Muteins of human lipocalin 2 with affinity for CTLA-4
|
US20120208755A1
(en)
|
2011-02-16 |
2012-08-16 |
Intarcia Therapeutics, Inc. |
Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
|
CN103476409A
(zh)
|
2011-03-31 |
2013-12-25 |
诺华股份有限公司 |
治疗丙肝病毒感染的阿拉泊韦
|
KR20140010097A
(ko)
|
2011-04-01 |
2014-01-23 |
노파르티스 아게 |
B형 간염 바이러스 단독 감염 또는 델타 간염 바이러스와의 조합 감염 및 연관된 간 질환의 치료
|
SG193908A1
(en)
|
2011-04-13 |
2013-11-29 |
Novartis Ag |
Treatment of hepatitis c virus infection with alisporivir
|
WO2013045460A1
(en)
|
2011-09-27 |
2013-04-04 |
Novartis Ag |
Alisporivr for treatment of hepatis c virus infection
|
US8889159B2
(en)
|
2011-11-29 |
2014-11-18 |
Gilead Pharmasset Llc |
Compositions and methods for treating hepatitis C virus
|
EP3842058B1
(en)
|
2011-12-13 |
2023-08-23 |
Pieris Pharmaceuticals GmbH |
Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors
|
US8809354B2
(en)
|
2011-12-31 |
2014-08-19 |
Sheikh Riazuddin |
3-amino-2-(4-nitrophenyl)-4-(3H)-quinazolinone or derivatives thereof for treating or preventing antiviral infections
|
JP2015509980A
(ja)
|
2012-03-14 |
2015-04-02 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Hcv−hiv同時感染患者集団のhcv感染症を治療するための併用療法
|
WO2013143581A1
(en)
|
2012-03-28 |
2013-10-03 |
Boehringer Ingelheim International Gmbh |
Combination therapy for treating hcv infection in specific patient subgenotype sub-population
|
US9522940B2
(en)
|
2012-05-23 |
2016-12-20 |
Pieris Pharmaceuticals Gmbh |
Lipocalin muteins with binding-affinity for glypican-3 (GPC-3) and use of lipocalin muteins for target-specific delivery to cells expressing GPC-3
|
EP3441400B1
(en)
|
2012-11-19 |
2022-07-20 |
Pieris Pharmaceuticals GmbH |
Novel specific-binding polypeptides and uses thereof
|
RU2015142437A
(ru)
|
2013-03-14 |
2017-04-27 |
Дайити Санкио Ко., Лтд |
Новые связывающие белки для pcsk9
|
CN106913865A
(zh)
|
2013-04-18 |
2017-07-04 |
阿尔莫生物科技股份有限公司 |
使用白细胞介素‑10治疗疾病和病症的方法
|
CA2914837A1
(en)
|
2013-06-17 |
2014-12-24 |
Armo Biosciences, Inc. |
Method for assessing protein identity and stability
|
SI3038601T1
(sl)
|
2013-08-27 |
2020-07-31 |
Gilead Pharmasset Llc |
Formulacija kombinacije dveh protivirusnih spojin
|
WO2015031316A1
(en)
|
2013-08-30 |
2015-03-05 |
Armo Biosciences, Inc. |
Methods of using interleukin-10 for treating diseases and disorders
|
JP6660297B2
(ja)
|
2013-11-11 |
2020-03-11 |
アルモ・バイオサイエンシーズ・インコーポレイテッド |
疾患及び障害を処置するためのインターロイキン−10の使用方法
|
US10927154B2
(en)
|
2014-01-13 |
2021-02-23 |
Pieris Pharmaceuticals Gmbh |
Multi-specific polypeptide useful for localized tumor immunomodulation
|
RU2723034C2
(ru)
|
2014-05-22 |
2020-06-08 |
ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ |
Новые полипептиды со специфическим связыванием и пути их применения
|
US10293043B2
(en)
|
2014-06-02 |
2019-05-21 |
Armo Biosciences, Inc. |
Methods of lowering serum cholesterol
|
US9889085B1
(en)
|
2014-09-30 |
2018-02-13 |
Intarcia Therapeutics, Inc. |
Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
|
EP3206713A4
(en)
|
2014-10-14 |
2018-06-27 |
Armo Biosciences, Inc. |
Interleukin-15 compositions and uses thereof
|
ES2941234T3
(es)
|
2014-10-22 |
2023-05-19 |
Armo Biosciences Inc |
Métodos de uso de la interleucina-10 para el tratamiento de enfermedades y trastornos
|
SG10201906859PA
(en)
|
2015-01-28 |
2019-08-27 |
Pieris Pharmaceuticals Gmbh |
Novel proteins specific for angiogenesis
|
WO2016126615A1
(en)
|
2015-02-03 |
2016-08-11 |
Armo Biosciences, Inc. |
Methods of using interleukin-10 for treating diseases and disorders
|
PE20171652A1
(es)
|
2015-02-18 |
2017-11-13 |
Sanofi Sa |
Nuevas proteinas especificas para pioverdina y pioquelina
|
MX2017014082A
(es)
|
2015-05-04 |
2018-06-28 |
Pieris Pharmaceuticals Gmbh |
Nuevas proteinas especificas para cd137.
|
KR20170138574A
(ko)
|
2015-05-04 |
2017-12-15 |
피어이스 파마슈티컬즈 게엠베하 |
항암 융합 폴리펩타이드
|
CA2980838A1
(en)
|
2015-05-18 |
2016-11-24 |
Pieris Pharmaceuticals Gmbh |
Anti-cancer fusion polypeptide
|
BR112017020961A2
(pt)
|
2015-05-18 |
2018-07-10 |
Pieris Pharmaceuticals Gmbh |
muteína, molécula de ácido nucleico, célula hospedeira, método de produção de uma muteína e método de ligação
|
JP7121496B2
(ja)
|
2015-05-28 |
2022-08-18 |
アルモ・バイオサイエンシーズ・インコーポレイテッド |
癌治療で使用するためのペグ化インターロイキン-10
|
EP3302354B1
(en)
|
2015-06-03 |
2023-10-04 |
i2o Therapeutics, Inc. |
Implant placement systems
|
EP3115371A1
(en)
|
2015-07-07 |
2017-01-11 |
Sanofi |
Fusion molecules
|
AU2016293101B2
(en)
|
2015-07-15 |
2022-06-16 |
Pieris Pharmaceuticals Gmbh |
Novel proteins specific for LAG-3
|
AU2016312510A1
(en)
|
2015-08-25 |
2018-03-08 |
Armo Biosciences, Inc. |
Methods of using Interleukin-10 for treating diseases and disorders
|
JP2019505565A
(ja)
|
2015-11-30 |
2019-02-28 |
ピエリス オーストラリア プロプライエタリー リミテッド |
新規の抗血管新生融合ポリペプチド
|
TW201725212A
(zh)
|
2015-12-10 |
2017-07-16 |
第一三共股份有限公司 |
特異性於降鈣素基因相關胜肽的新穎蛋白
|
BR112018073511A2
(pt)
|
2016-05-16 |
2019-03-26 |
Intarcia Therapeutics, Inc. |
polipeptídeos seletivos do receptor de glucagon e métodos de uso dos mesmos
|
USD840030S1
(en)
|
2016-06-02 |
2019-02-05 |
Intarcia Therapeutics, Inc. |
Implant placement guide
|
USD860451S1
(en)
|
2016-06-02 |
2019-09-17 |
Intarcia Therapeutics, Inc. |
Implant removal tool
|
CA3028683A1
(en)
*
|
2016-06-20 |
2017-12-28 |
Ambrx, Inc. |
Pegylated porcine interferon and methods of use thereof
|
WO2018035281A1
(en)
|
2016-08-17 |
2018-02-22 |
North Carolina State University |
Northern-southern route to synthesis of bacteriochlorins
|
WO2018087108A1
(en)
|
2016-11-09 |
2018-05-17 |
Pieris Pharmaceuticals Gmbh |
Proteins specific for cd137
|
WO2018102252A1
(en)
|
2016-11-30 |
2018-06-07 |
North Carolina State University |
Methods for making bacteriochlorin macrocycles comprising an annulated isocyclic ring and related compounds
|
CN110225762A
(zh)
|
2017-01-03 |
2019-09-10 |
因塔西亚制药公司 |
包括glp-1受体激动剂的连续施用和药物的共同施用的方法
|
CN110402252A
(zh)
|
2017-01-18 |
2019-11-01 |
皮里斯制药有限公司 |
对lag-3具有结合亲和力的脂质运载蛋白突变蛋白
|
AU2019315703A1
(en)
|
2018-07-31 |
2020-12-10 |
Les Laboratoires Servier |
Novel fusion protein specific for CD137 and PD-L1
|
EP3931209A1
(en)
|
2019-02-26 |
2022-01-05 |
Pieris Pharmaceuticals GmbH |
Novel fusion proteins specific for cd137 and gpc3
|
US20230227568A1
(en)
|
2020-06-05 |
2023-07-20 |
Pieris Pharmaceuticals Gmbh |
Multimeric immunomodulator targeting 4-1bb
|
CA3214220A1
(en)
|
2021-04-08 |
2022-10-13 |
Marina PAVLIDOU |
Novel lipocalin muteins specific for connective tissue growth factor (ctgf)
|
WO2022243341A1
(en)
|
2021-05-18 |
2022-11-24 |
Pieris Pharmaceuticals Gmbh |
Lipocalin muteins with binding affinity for ox40
|
WO2024064713A1
(en)
|
2022-09-21 |
2024-03-28 |
Seagen Inc. |
Novel fusion protein specific for cd137 and cd228
|